Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04323475
Registration number
NCT04323475
Ethics application status
Date submitted
20/03/2020
Date registered
26/03/2020
Date last updated
22/12/2021
Titles & IDs
Public title
Phage Therapy for the Prevention and Treatment of Wound Infections in Burned Patients
Query!
Scientific title
A Randomized, Open-Label, Active Controlled Study to Evaluate the Safety and Tolerability of a Phage Cocktail-SPK Therapy in Second Degree Burn Wounds in Adult Patients
Query!
Secondary ID [1]
0
0
PGX-18001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Wound Infection
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Studies of infection and infectious agents
Query!
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Infection
0
0
0
0
Query!
Sexually transmitted infections
Query!
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - Bacteriophage cocktail spray
Treatment: Drugs - Xeroform
Active Comparator: Standard of Care - Standard of care consists of Xeroform primary dressing, a Melolin interface and a crepe. Kenacomb will be used for participants with diagnosed or suspected local infections.
Experimental: Cocktail-SPK and standard of care - The experimental drug consists of Cocktail-SPK used as an adjunct to the standard of care. Standard of care consists of Xeroform primary dressing, a Melolin interface and a crepe. Kenacomb will be used for participants with diagnosed or suspected local infections.
Other interventions: Bacteriophage cocktail spray
Study intervention consists of a dosage-metered airless spray containing a cocktail of 14 bacteriophages at a concentration of 1.4 x 10^8 PFU/mL for an effective dosage of 2.5 x10^5 PFU/cm^2 of burned area. The study intervention will be applied in conjunction with standard of care.
Treatment: Drugs: Xeroform
Standard of care will consist of Xeroform primary dressing and Kenacomb topical antibiotic cream (for wounds with signs of localized infection)
Query!
Intervention code [1]
0
0
Other interventions
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Incidence of Treatment-Emergent Adverse Events coded by MedDra
Query!
Assessment method [1]
0
0
Safety of Phage cocktail-SPK will be measured by the number and percent of treatment related adverse events
Query!
Timepoint [1]
0
0
At least 14 days
Query!
Primary outcome [2]
0
0
Incidence of treatment discontinuation due to adverse events
Query!
Assessment method [2]
0
0
Tolerability of Phage Cocktail-SPK will be measured by the percent premature discontinuation from the study intervention due to treatment emergent Adverse Events
Query!
Timepoint [2]
0
0
14 days
Query!
Secondary outcome [1]
0
0
Assess if Phage Cocktail-SPK can prevent or reduce S. aureus, P. aeruginosa, or K. pneumoniae wound colonization.
Query!
Assessment method [1]
0
0
Change in the incidence of positive wound cultures for S. aureus, P. aeruginosa, K. pneumoniae;
Query!
Timepoint [1]
0
0
14 days
Query!
Eligibility
Key inclusion criteria
1. Provision of signed and dated informed consent form
2. Stated willingness to comply with all study procedures and lifestyle considerations,
and availability for the duration of the study
3. Male or female, aged 18 years or older presenting at the emergency department,
out-patient burn department or in-hospital patients with a thermal second degree burn
wounds (American Burn Association severity classification).
4. Patients with a burn wound covering less than 10% of their total body surface area
(TBSA) and present within 7 days of their injury, with or without signs of local
infection, expected to heal without the need for surgery.
5. For females of reproductive potential: use of a highly effective contraception for at
least 1 month prior to screening and agreement to use such a method during study
participation and for an additional 4 weeks after the end of administration of the
study intervention
6. For males of reproductive potential: use of condoms or other methods to ensure
effective contraception with partner
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Current use of dressings containing silver or nanocrystalline silver
2. Pregnancy or lactation
3. Clinical evidence of invasive infection based on American Burn Association consensus
conference(Greenhalgh et al., 2007).
4. Burn wounds present in anatomic locations such as burns on the face, hands, feet,
genitals, perineum, as well as sites at high risk for developing compartment syndrome
(deep circumferential extremity burns).
5. Known allergic reactions to components of Xeroform or Kenacomb.
6. Patients diagnosed with Type I or Type II diabetes.
7. Treatment with another investigational drug or other intervention within 30 days
8. Intercurrent condition requiring a high dose of chronic corticosteroid therapy,
immunosuppressive medication, oncologic chemotherapy.
9. Patients who have additional uncontrolled serious medical or psychiatric illness
determined by the investigators where the patient is unfit to receive PGX-0100.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
1/01/2022
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/08/2023
Query!
Actual
Query!
Sample size
Target
12
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Phagelux Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The central aim of this trial is to investigate the safety and tolerability of Phage
Cocktail-SPK as an adjunct to standard therapy for the prevention and treatment of burns
susceptible to infection/or infected by S. aureus, P. aeruginosa, or K. pneumoniae species.
It is hypothesized that no adverse events, clinical abnormalities, or changes in laboratory
tests results related to the application of Phage Cocktail SPK Spray will be observed.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04323475
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
Nancy Tawil, PhD
Query!
Address
0
0
Phagelux Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Nancy Tawil, PhD
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
18002430116
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04323475
Download to PDF